Teachers Retirement System of The State of Kentucky Lowers Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Teachers Retirement System of The State of Kentucky lowered its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 6.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 117,361 shares of the medical device company's stock after selling 7,888 shares during the quarter. Teachers Retirement System of The State of Kentucky's holdings in DexCom were worth $9,127,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. Versant Capital Management Inc bought a new position in DexCom in the 4th quarter valued at about $25,000. Private Trust Co. NA lifted its holdings in DexCom by 266.3% during the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock worth $26,000 after purchasing an additional 245 shares during the last quarter. TD Private Client Wealth LLC boosted its stake in DexCom by 62.8% in the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock valued at $34,000 after purchasing an additional 167 shares during the period. Larson Financial Group LLC grew its holdings in DexCom by 40.5% in the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after buying an additional 137 shares in the last quarter. Finally, Heck Capital Advisors LLC acquired a new position in DexCom in the 4th quarter valued at $38,000. 97.75% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

DXCM has been the subject of several recent research reports. Morgan Stanley boosted their price target on DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research note on Friday, February 14th. Baird R W upgraded DexCom from a "hold" rating to a "strong-buy" rating in a research report on Thursday, January 16th. Mizuho assumed coverage on shares of DexCom in a report on Thursday, April 10th. They issued an "outperform" rating and a $85.00 target price on the stock. Canaccord Genuity Group boosted their target price on shares of DexCom from $99.00 to $103.00 and gave the company a "buy" rating in a research report on Friday, February 14th. Finally, Citigroup increased their price target on shares of DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a research report on Tuesday, March 4th. Five equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $99.00.

DexCom Trading Up 5.9 %

NASDAQ:DXCM traded up $3.92 on Thursday, reaching $70.78. 3,922,797 shares of the stock traded hands, compared to its average volume of 4,242,458. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $139.24. The company's 50 day moving average is $73.46 and its 200-day moving average is $76.61. The firm has a market capitalization of $27.75 billion, a price-to-earnings ratio of 49.50, a price-to-earnings-growth ratio of 2.30 and a beta of 1.50.

DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Equities research analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Activity at DexCom

In related news, EVP Michael Jon Brown sold 13,000 shares of the company's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $914,940.00. Following the sale, the executive vice president now owns 105,602 shares in the company, valued at $7,432,268.76. This represents a 10.96 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Jacob Steven Leach sold 2,634 shares of DexCom stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $228,920.94. Following the transaction, the chief operating officer now owns 268,644 shares of the company's stock, valued at $23,347,850.04. This trade represents a 0.97 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 105,009 shares of company stock worth $8,044,178 in the last quarter. Company insiders own 0.32% of the company's stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.